News | Nuclear Imaging | June 08, 2016

Nuclear Medicine Market Shows Slow Growth Since 2014

Medraysintell report says growth has been affected the molybdenum-99 shortage, exchanges rates

nuclear medicine, global market, radiopharmaceuticals, MEDraysintell, SNMMI 2016

June 8, 2016 — MEDraysintell estimates that the global market for nuclear medicine (radiopharmaceuticals) reached $4.3 billion in 2015, growing just over 2 percent a year between 2013 and 2015. This slow growth is primarily driven by lower revenues from technetium-99m-related products and an unfavorable impact from U.S. dollar exchange rates versus major currencies.

This slow progression is compensated by a robust increase of radiotherapeutics, which have grown by about 60 percent a year from 2013 to 2015, mostly driven by one product, Xofigo from Bayer. Without this exchange rate influence, MEDraysintell estimates that the nuclear medicine market would have reached over $4.7 billion in 2015, thereby exhibiting an annual growth of more than 7 percent for the period 2013-2015.

While it has been stable the last year, the global nuclear medicine market is expected to climb to $25 billion by 2030. Several factors indicate an increasing demand for nuclear medicine procedures, including a wider use of nuclear medicine around the world (other applications besides oncology and cardiology) and the introduction of new radiopharmaceuticals. The molybdenum-99 shortage issue, which will be solved within the next two years with domestic U.S. reactors coming online, will also influence additional growth. Yet, the most important factor that will shape the future growth of the nuclear medicine market is the launch of new-generation therapeutic radiopharmaceuticals.

All these topics are extensively covered in the new Nuclear Medicine World Market Report & Directory, Edition 2016 to be published shortly after the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2016 annual meeting, June 11-15 in San Diego. The 990–page report and directory describes and analyzes over 360 radiopharmaceuticals and radionuclides and more than 160 companies and institutions active in nuclear medicine.

For more information: www.medraysintell.org

Related Content

Amazon, Berkshire Hathaway and JPMorgan Chase to Form New Healthcare Company
News | Business | January 30, 2018
January 30, 2018 — Amazon , Berkshire Hathaway and JPMorgan Chase & Co.
News | Business | January 16, 2018
American College of Cardiology (ACC) Chief Executive Officer Shalom “Shal” Jacobovitz will be leaving the College...
CMS Launches New Voluntary Bundled Payments Model
News | Business | January 10, 2018
The Centers for Medicare & Medicaid Services (CMS) Center for Medicare and Medicaid Innovation (Innovation Center)...
Toshiba Medical Systems Changes Name to Canon Medical Systems Corp.
News | Business | January 08, 2018
January 8, 2018 — Canon Inc. and Canon Medical Systems Corp.
CMS Announces Final Changes, Cancellations of Mandatory Bundled Payment Models
News | Business | December 21, 2017
The Centers for Medicare & Medicaid Services (CMS) last week finalized the cancellation of the mandatory hip...
Catheter reprocessing can reduce costs in the cath and EP lab.
Feature | Business | December 19, 2017 | Lars Thording
As payers and other healthcare entities look to better manage costs, especially in the acute care setting, it is impo
FDA Issues Final Guidance on Investigational Device Exemption Categorization
News | Business | December 19, 2017
The U.S. Food and Drug Administration (FDA) recently issued a final guidance, “FDA Categorization of Investigational...
Congressional Budget Office Finds cutting ACA insurance mandate will cause 13 million people to become uninsured, higher insurance premiums. American Heart Association (AHA), #AHA2017
News | Business | December 06, 2017
December 6, 2017 — At the American Heart Association (AHA) annual meeting in November, a group of 16 non-partisan pat
5 Tips for Medical Device Engineers on FDA Design Controls
Feature | Business | November 24, 2017 | Jon Speer
If you are an engineer in the medical device industry, you probably have a love/hate relationship with the FDA-mandat
Videos | Business | November 09, 2017
A discussion with Peter L.
Overlay Init